Indivior clears key resistance level, shares extend strong NASDAQ run

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 21:19.

Indivior (GB00BYZ0C031) is trading close to its recent highs on NASDAQ, with the shares last at 41.47 US dollars at the June 24 close. Technical data place the stock between support at 35.36 dollars and resistance at 44.62 dollars, underscoring the current trading range on the US market.

What the technicals show

According to TradingKey, Indivior shares closed at 41.47 dollars on June 24, up 3.78 percent for the day and leaving the stock in the upper part of its recent range. The same analysis cites a resistance level at 44.62 dollars and support at 35.36 dollars, framing the short- to medium-term band for NASDAQ traders.

Momentum indicators are currently robust. TradingKey assigns Indivior a price momentum score of 9.54, ranking it 18th out of 157 names in the pharmaceuticals industry. The site also notes that the moving averages from 5 to 200 days generate six buy signals and no sell signals, while a separate model counts three buy and one sell signal at present.

Analysts and valuation backdrop

On the analyst side, Barclays initiated coverage of Indivior on June 18 with an Overweight rating and a 46 dollar price target, according to a press summary of the bank’s note. That target sits modestly above the latest NASDAQ close and complements the constructive technical picture seen in recent weeks.

Zacks currently assigns Indivior a Rank #1 (Strong Buy) in its system, citing unchanged earnings per share estimates of 4.05 dollars for 2026 and 4.27 dollars for 2027 over the past 30 days. At the June 24 close of 41.47 dollars, that implies a forward price-earnings multiple in the low double digits on the 2026 estimate.

The business behind the ticker

Indivior focuses on treatments for substance use disorders and serious mental illnesses, with flagship products in medication-assisted therapy for opioid dependence. The group’s portfolio centers on buprenorphine-based formulations that are designed to support long-term recovery in patients.

Where the stock trades today

The Indivior shares (GB00BYZ0C031) most recently closed on NASDAQ at 41.47 US dollars on 2026-06-24, while intra-day data on June 25 showed quotes around the 40 to 41 dollar mark.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research and, where appropriate, consult a qualified financial advisor.